EUVIMEDEUVIMED entdecken
Multizentrische Studie

Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Takanori Suzuki, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Atsunori Kusakabe, Izumi Hasegawa, Kiyoto Narita, Tsutomu Mizoshita, Yoshihide Kimura und 7 weitere

Oncology · 2025

DOI: 10.1159/000546515 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology, 2025. Verfasst von Takanori Suzuki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Bevacizumab, Carcinoma, Hepatocellular, Antibodies, Monoclonal, Humanized.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atezolizumab plus bevacizumab (ATZ+BV) is used for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage B unresectable hepatocellular carcinoma (u-HCC) patients. However, the efficacy of ATZ+BV in various BCLC stage B conditions, especially the up-to-seven criteria in/out, has not been fully investigated.

Methods

We enrolled 83 BCLC stage B u-HCC patients with Child-Pugh class A who were treated with ATZ+BV as the first-line systemic chemotherapy in the study. All patients were evaluated for initial responses by dynamic computed tomography or magnetic resonance imaging after the initiation of ATZ+BV, and therapeutic efficacy was assessed.

Results

When stratified by up-to-seven criteria, progression-free survival (PFS) was significantly prolonged in patients with up-to-seven in (in vs. out: median 21.0 vs. 8.2 months, P = 0.006), and the Cox proportional hazard model showed that up-to-seven out/in was the significant factor contributing to PFS (out vs. in: HR 2.58, P = 0.007). We next evaluated PFS stratified by the maximum intrahepatic tumor diameter and number of intrahepatic tumors, which constitute the up-to-seven criteria. The number of tumors was a significant factor contributing to PFS (> 7 vs. ≤ 7: HR 1.75, P = 0.040), but maximum tumor size was not (> 5 cm vs. ≤ 5 cm: HR 1.19, P = 0.588).

Conclusions

In BCLC stage B u-HCC patients treated with ATZ+BV, a high number of intrahepatic tumors was associated with poor PFS. Therefore, it may be better to consider additional treatment strategies in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsBevacizumabCarcinoma, HepatocellularAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedNeoplasm StagingProgression-Free SurvivalAdult

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabHepatocellular carcinomaUnresectable hepatocellular carcinoma

Substanzen

BevacizumabAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, matsuura@med.nagoya-cu.ac.jp.
  • Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
  • Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
  • Department of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.
  • Department of Gastroenterology, Chukyo Hospital, Nagoya, Japan.

Zitieren

APA

Suzuki, T., Matsuura, K., Kato, D., Hayashi, K., Okayama, K., Okumura, F., Sobue, S., Kusakabe, A., Hasegawa, I., Narita, K., Mizoshita, T., Kimura, Y., Sato, R., Kondo, H., Ozasa, A., Kawamura, H., Fujiwara, K., Nojiri, S., & Kataoka, H. (2025). Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis. Oncology. https://doi.org/10.1159/000546515

Vancouver

Suzuki T, Matsuura K, Kato D, Hayashi K, Okayama K, Okumura F, et al. Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis. Oncology. 2025. doi:10.1159/000546515

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Takanori and Matsuura, Kentaro and Kato, Daisuke and Hayashi, Katsumi and Okayama, Kohei and Okumura, Fumihiro and Sobue, Satoshi and Kusakabe, Atsunori and Hasegawa, Izumi and Narita, Kiyoto and Mizoshita, Tsutomu and Kimura, Yoshihide and Sato, Ryo and Kondo, Hiromu and Ozasa, Atsushi and Kawamura, Hayato and Fujiwara, Kei and Nojiri, Shunsuke and Kataoka, Hiromi},
  title = {Number of Tumors Stratifies the Therapeutic Response to Atezolizumab Plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000546515}
}
Kostenlos starten →